# A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis

> **NCT02313883** · PHASE1,PHASE2 · COMPLETED · sponsor: **Geistlich Pharma AG** · enrollment: 127 (actual)

## Conditions studied

- Periodontitis

## Interventions

- **DRUG:** PerioSept(r)

## Key facts

- **NCT ID:** NCT02313883
- **Lead sponsor:** Geistlich Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2018-07-02
- **Final completion:** 2018-07-02
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2019-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02313883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02313883, "A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02313883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*